GABRG2 and hepatocellular carcinoma: Here, we used several methods to inhibit intracellular ACBP/DBI, namely, its knockdown in HCC cell lines and its tamoxifen-inducible knockout in mice, as well as methods to interfere with extracellular ACBP/DBI, namely, its antibody-mediated neutralization and the mutation of its receptor GABRG2.